Press Releases

9 June 2022

Coave Therapeutics and ABL enter into strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for process development of AAV-based gene therapy

Read more
3 May 2022

Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT

Read more
27 April 2022

Coave Therapeutics will be presenting an abstract at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held in Denver, Colorado 1-4 May 2022. The meeting will also be available for virtual attendees 11-12 May.

Read more
13 April 2022

Coave Therapeutics to Present at Cell & Gene Meeting on the Mediterranean

Read more
15 November 2021

Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Françon PhD as Chief Operating Officer

Read more
12 October 2021

Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board

Read more
16 September 2021

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

Read more
21 July 2021

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform

Read more
WordPress Cookie Plugin by Real Cookie Banner